SS-31 (Elamipretide).
Targets mitochondria directly. In clinical trials for heart failure.
Reviewed March 2026
- Category
- Peptide
- Also filed under
- Mitochondrial functionCardioprotectionExercise capacity
What SS-31 (Elamipretide) is, and what it does.
- Does it work
- This is an investigational injectable peptide used under medical supervision. It suits research settings rather than a daily supplement routine, since it is not orally available.
- How much to take
- The record shows 10mg to 40mg a day, with 80mg as a research condition. It is a peptide with negligible oral availability, so those figures come from injected use.
- Time to feel it
- Changes in exercise tolerance reported in trial settings took weeks of daily dosing. Nobody has measured a timeline for any oral form.
- The first dose
- Nothing has been characterised for day one outside a clinical setting. It reaches the inner mitochondrial membrane quickly, but that is chemistry rather than sensation.
- With regular use
- Most effects take 2-8 weeks. Be patient.
- How well tolerated
- Generally well tolerated. Check with your doctor if on medications.
- How it feels
- Improved energy and exercise tolerance in clinical trials.
- The overlooked benefit
- Its uptake into the inner mitochondrial membrane does not depend on membrane potential, so it still reaches mitochondria that have lost their charge gradient.
10 to 40mg a day is where SS-31 (Elamipretide) works.
Source: Szeto, AAPS J, 2006; Stealth BioTherapeutics clinical trials for mitochondrial disease
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
SS-31 (Elamipretide) has emerging evidence. Based on 181+ studies.
- Binding to cardiolipin in the inner mitochondrial membraneIn vitro study
- Cristae architecture and reduced electron leakAnimal study
- Lowering cardiolipin-bound cytochrome c peroxidase activityIn vitro study
- Exercise tolerance measuresRandomised trial
- Skeletal muscle mitochondrial functionRandomised trial
Questions people ask about SS-31 (Elamipretide).
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
SS-31 binds cardiolipin and helps hold cristae structure and respiratory supercomplexes together, which is the environment ubiquinol shuttles electrons through. Structural support and electron carrier supply address different halves of the same membrane.
NAD precursors raise cofactor availability for the electron transport chain and sirtuin signalling, while SS-31 acts on cristae architecture rather than cofactor supply. The two touch separate limits on mitochondrial output.
PQQ signals through PGC-1alpha toward making new mitochondria while SS-31 works on the membrane structure of existing ones. Building capacity and maintaining capacity are different levers.
Urolithin A promotes mitophagy, the clearance of damaged mitochondria, while SS-31 supports the cardiolipin-dependent structure of those that remain. Clearance and maintenance are distinct arms of mitochondrial quality control.
Complex I carries FMN and complex II carries FAD, and both are built from riboflavin. Stabilising the membrane those complexes sit in does nothing if the flavin cofactors are short. This is textbook cofactor dependency rather than a tested combination.
Nearly every ATP-handling step runs on the Mg-ATP complex, not on free ATP. Any intervention aimed at oxidative phosphorylation depends on adequate magnesium for the output to be usable. The relationship is cofactor supply, not a demonstrated synergy.
Fatty acids cannot cross the inner membrane without the carnitine shuttle, and the carnitine-acylcarnitine translocase sits in that membrane alongside cardiolipin. A compound that binds cardiolipin and preserves membrane organisation and a compound that supplies the shuttle substrate address adjacent steps in fat oxidation. Human data on the pair are absent.
Cardiolipin is synthesised inside the mitochondrion from CDP-diacylglycerol and phosphatidylglycerol, and it is remodelled using acyl chains drawn from phosphatidylcholine by tafazzin. SS-31 binds the cardiolipin that already exists; phospholipid substrate supply is what determines how much there is to bind. The link is biosynthetic, not a tested pairing.
Mitochondrial creatine kinase is associated with the inner membrane and depends on local ATP output. Raising the creatine pool supports phosphate transfer downstream of oxidative phosphorylation, a different step from membrane stabilisation. Combination evidence does not exist.
Taurine-modified mitochondrial tRNA is needed to translate the subunits of the respiratory complexes, and taurine also influences membrane calcium handling. That places it upstream of the complexes whose organisation SS-31 preserves. This row is biochemistry, not clinical evidence.
Peroxidation of cardiolipin acyl chains is one route by which inner-membrane organisation is lost. A membrane-spanning carotenoid intercepts radicals in that same lipid phase, while SS-31 binds cardiolipin directly. The two target the same lipid from different angles; no human combination data exist.
Mitochondria import glutathione rather than making it in place, and that pool is what glutathione peroxidase uses to clear hydrogen peroxide from electron leak. SS-31 is described as lowering the peroxidase-like activity of cardiolipin-bound cytochrome c, which lowers one source of that stress. Both act on mitochondrial peroxide handling, at separate points.
Melatonin accumulates in the mitochondrial matrix and membranes at concentrations above plasma and reacts directly with oxidants. That overlaps in location with a cardiolipin-binding peptide. The overlap is anatomical and chemical; no trial of the pair is available.
Both of those dehydrogenase complexes sit in the mitochondrial matrix and cannot run without their lipoamide arm. Supplemental lipoic acid also enters the cellular thiol pool. This is a cofactor and redox relationship rather than a demonstrated combination effect.
Mitochondrial quality control has two arms, keeping existing organelles functional and clearing the ones that are not. A cardiolipin-binding peptide addresses the first; spermidine-induced autophagy addresses the second. Externalised cardiolipin is also a recognition signal in mitophagy, so the interaction could run either way and has not been measured in people.
Nothing specific on file for SS-31 (Elamipretide). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What SS-31 (Elamipretide) actually does.
It is a four-amino-acid synthetic peptide built to slip through cell membranes and collect in the inner wall of the mitochondrion without needing an electrical gradient to pull it there.
It sticks to cardiolipin, a fat found only in the inner mitochondrial membrane, rather than to a protein receptor.
Unnatural building blocks make it survive enzymes that chew up normal peptides, but digestion still applies, so it has been given by injection or as eye drops in research rather than swallowed.
Cardiolipin holds the energy-producing machinery in place. Keeping it organised is the proposed reason membrane structure and electron flow hold up better.
Getting SS-31 (Elamipretide) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Pooling human trials of mitochondria-targeted antioxidants as a class, the review examined effects on blood sugar control, vascular measures and markers of oxidative stress.Meta-analysis. Mason et al., 2022 (Diabetes, obesity & metabolism). PMID 35165982 ↗
- Elamipretide added during in vitro production of porcine embryos changed mitochondrial and developmental measures in the culture system; the authors describe the protective potential as in vitro.In vitro study. Nguyen et al., 2025 (Animals). PMID 40941292 ↗
- A review of mitochondria-targeted compounds that names elamipretide among the cardiolipin-binding, mitochondrially targeted agents under investigation; it is a summary of the field rather than new data.Narrative review. Lores-Arnaiz et al., 2026 (Biology). PMID 41677699 ↗
These are the studies our verdict leans on, chosen from the 205 we read for SS-31 (Elamipretide). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.